These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 29802399

  • 1. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
    Goto T, Itoh M, Suganami T, Kanai S, Shirakawa I, Sakai T, Asakawa M, Yoneyama T, Kai T, Ogawa Y.
    Sci Rep; 2018 May 25; 8(1):8157. PubMed ID: 29802399
    [Abstract] [Full Text] [Related]

  • 2. CD11c+ resident macrophages drive hepatocyte death-triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis.
    Itoh M, Suganami T, Kato H, Kanai S, Shirakawa I, Sakai T, Goto T, Asakawa M, Hidaka I, Sakugawa H, Ohnishi K, Komohara Y, Asano K, Sakaida I, Tanaka M, Ogawa Y.
    JCI Insight; 2017 Nov 16; 2(22):. PubMed ID: 29202448
    [Abstract] [Full Text] [Related]

  • 3. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M.
    World J Gastroenterol; 2018 Jan 14; 24(2):179-194. PubMed ID: 29375204
    [Abstract] [Full Text] [Related]

  • 4. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H, Will S, Guionaud S, Boland ML, Oldham S, Ravn P, Celeste A, Trevaskis JL.
    Mol Metab; 2017 Nov 14; 6(11):1360-1370. PubMed ID: 29107284
    [Abstract] [Full Text] [Related]

  • 5. Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice.
    Konuma K, Itoh M, Suganami T, Kanai S, Nakagawa N, Sakai T, Kawano H, Hara M, Kojima S, Izumi Y, Ogawa Y.
    PLoS One; 2015 Nov 14; 10(3):e0121528. PubMed ID: 25816330
    [Abstract] [Full Text] [Related]

  • 6. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis.
    Komiya C, Tanaka M, Tsuchiya K, Shimazu N, Mori K, Furuke S, Miyachi Y, Shiba K, Yamaguchi S, Ikeda K, Ochi K, Nakabayashi K, Hata KI, Itoh M, Suganami T, Ogawa Y.
    Sci Rep; 2017 Mar 17; 7():44754. PubMed ID: 28303974
    [Abstract] [Full Text] [Related]

  • 7. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
    Huang S, Wu Y, Zhao Z, Wu B, Sun K, Wang H, Qin L, Bai F, Leng Y, Tang W.
    Metabolism; 2021 Jul 17; 120():154797. PubMed ID: 33984334
    [Abstract] [Full Text] [Related]

  • 8. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
    Briand F, Brousseau E, Quinsat M, Burcelin R, Sulpice T.
    Eur J Pharmacol; 2018 Jan 05; 818():449-456. PubMed ID: 29155143
    [Abstract] [Full Text] [Related]

  • 9. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis.
    Roth JD, Feigh M, Veidal SS, Fensholdt LK, Rigbolt KT, Hansen HH, Chen LC, Petitjean M, Friley W, Vrang N, Jelsing J, Young M.
    World J Gastroenterol; 2018 Jan 14; 24(2):195-210. PubMed ID: 29375205
    [Abstract] [Full Text] [Related]

  • 10. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A, Biagioli M, Marchianò S, Fiorucci C, Zampella A, Monti MC, Scarpelli P, Ricci P, Distrutti E, Fiorucci S.
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct 14; 1864(10):1422-1437. PubMed ID: 31325638
    [Abstract] [Full Text] [Related]

  • 11. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice.
    Li J, Liu C, Zhou Z, Dou B, Huang J, Huang L, Zheng P, Fan S, Huang C.
    Phytother Res; 2021 Jun 14; 35(6):3351-3364. PubMed ID: 33784797
    [Abstract] [Full Text] [Related]

  • 12. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
    Adorini L, Rigbolt K, Feigh M, Roth J, Erickson M.
    PLoS One; 2024 Jun 14; 19(4):e0300809. PubMed ID: 38662778
    [Abstract] [Full Text] [Related]

  • 13. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.
    Zhou J, Cui S, He Q, Guo Y, Pan X, Zhang P, Huang N, Ge C, Wang G, Gonzalez FJ, Wang H, Hao H.
    Nat Commun; 2020 Jan 13; 11(1):240. PubMed ID: 31932588
    [Abstract] [Full Text] [Related]

  • 14. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.
    Rodrigues PM, Afonso MB, Simão AL, Carvalho CC, Trindade A, Duarte A, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CM, Castro RE.
    Cell Death Dis; 2017 Apr 13; 8(4):e2748. PubMed ID: 28406477
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D.
    Gastroenterology; 2013 Sep 13; 145(3):574-82.e1. PubMed ID: 23727264
    [Abstract] [Full Text] [Related]

  • 16. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    Ijssennagger N, Janssen AWF, Milona A, Ramos Pittol JM, Hollman DAA, Mokry M, Betzel B, Berends FJ, Janssen IM, van Mil SWC, Kersten S.
    J Hepatol; 2016 May 13; 64(5):1158-1166. PubMed ID: 26812075
    [Abstract] [Full Text] [Related]

  • 17. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
    Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst I, Windmolders P, Farre R, Wenes M, Mazzone M, Nevens F, van Grunsven LA, Trebicka J, Laleman W.
    Sci Rep; 2016 Sep 16; 6():33453. PubMed ID: 27634375
    [Abstract] [Full Text] [Related]

  • 18. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
    Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, Mileti E, Galbiati M, Invernizzi P, Adorini L, Penna G, Rescigno M.
    J Hepatol; 2019 Dec 16; 71(6):1216-1228. PubMed ID: 31419514
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of hepatic function using dynamic contrast-enhanced magnetic resonance imaging in melanocortin 4 receptor-deficient mice as a model of nonalcoholic steatohepatitis.
    Yamada T, Kashiwagi Y, Rokugawa T, Kato H, Konishi H, Hamada T, Nagai R, Masago Y, Itoh M, Suganami T, Ogawa Y, Abe K.
    Magn Reson Imaging; 2019 Apr 16; 57():210-217. PubMed ID: 30465867
    [Abstract] [Full Text] [Related]

  • 20. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW, Lynch KD.
    Br Med Bull; 2020 May 15; 133(1):95-104. PubMed ID: 32282030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.